<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103012</url>
  </required_header>
  <id_info>
    <org_study_id>050082</org_study_id>
    <secondary_id>05-CC-0082</secondary_id>
    <nct_id>NCT00103012</nct_id>
  </id_info>
  <brief_title>Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers</brief_title>
  <official_title>The Influence of Concurrent Administration of Echinacea Purpurea, Ginkgo Biloba, or Panax Ginseng on the Steady State Pharmacokinetic Profile of Lopinavir/Ritonavir in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the interaction of the HIV combination medication lopinavir/ritonavir
      with the herbal products echinacea, ginseng, and ginkgo biloba. Patients with HIV infection
      often take herbal products and dietary supplements in addition to their doctor-prescribed
      medicines to treat the disease, lessen the side effects of anti-viral drugs, and improve
      their overall well being. Alternative medicines such as these may, however, interfere with
      the elimination of lopinavir/ritonavir from the body, causing either higher or lower blood
      levels of these drugs than would be expected. This study will assess in healthy subjects any
      potential harms of taking echinacea, ginseng, or ginkgo biloba together with
      lopinavir/ritonavir.

      Healthy normal volunteers between 18 and 50 years of age may be eligible for this study.
      Candidates are screened with a history, physical examination, and blood tests, including an
      HIV test and a pregnancy test for women. Pregnant women are excluded from the study.
      Participants come to the NIH Clinical Center after fasting overnight for the following
      procedures:

      Visits 1 and 2: A catheter (plastic tube) is placed in an arm vein to collect blood samples.
      After the first sample is drawn, the subject takes 8 mg of midazolam syrup and two
      fexofenadine tablets. Midazolam is a sedative, and fexofenadine (Allegra) is a medicine used
      to treat allergies. Subjects are given breakfast an hour after taking the drugs. Blood
      samples are collected at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8 and 24 hours after taking
      the drugs to measure blood levels of fexofenadine. An extra sample is collected at the 4-hour
      mark to measure the midazolam level. The catheter is removed after the 8-hour blood draw and
      subjects are dismissed home. They return the following morning (visit 2) for the 24-hour
      blood draw.

      Visit 3: From 7 to 28 days after visit 1, subjects begin taking lopinavir/ritonavir capsules
      twice a day by mouth for a total of 29.5 days. On day 15 they return to the clinic for
      lopinavir/ritonavir blood levels as were done for fexofenadine, except that samples are
      collected once before breakfast and then at 0.5, 1, 2, 3, 4, 6, 8 and 12 hours after the
      lopinavir/ritonavir dose. An extra sample is collected for routine tests. The catheter is
      removed after the 12-hour draw and the subject is dismissed home.

      The next morning, subjects begin taking one of the following: echinacea 500 mg 3 times a day;
      ginkgo biloba 120 mg twice a day; or ginseng 500 mg 3 times a day for 28 days.

      Visit 4: On the last day of taking lopinavir/ritonavir, subjects return to the clinic again
      for blood level measurements of these drugs as on visit 3, except that the catheter is
      removed and the subject dismissed home after the 8-hour blood draw.

      Visits 5 and 6: On the last day of taking the herbal supplement, subjects return to the
      clinic for repeat measurement of fexofenadine and midazolam levels, as described in visits 1
      and 2. At the final visit (visit 6) an additional blood sample is collected for repeat
      laboratory testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with HIV commonly use herbal products and dietary supplements in addition to
      medications prescribed by their physicians. Up to 73% of patients with HIV have reported
      using some form of complementary or alternative medicine. As such, the potential for
      clinically significant drug interactions between herbs and antiretrovirals is becoming
      increasingly appreciated. Despite this awareness, little is known about the effect of
      commonly used herbal products, such as echinacea, ginkgo biloba, and ginseng, on
      antiretroviral pharmacokinetics. Interacting herbal supplements have the potential to alter
      protease inhibitor (PI) plasma concentrations, as has been shown with St. John's Wort and
      garlic. Drug interactions may potentially increase antiretroviral concentrations, putting
      patients at risk for toxicities, or lower drug concentrations below the threshold of viral
      susceptibility, putting patients in jeopardy of antiretroviral failure. The protease
      inhibitors lopinavir and ritonavir both rely principally on cytochrome P450 (CYP) 3A4
      metabolism for their elimination. In addition, both drugs are substrates for the transport
      protein p-glycoprotein (P-gp), which may also contribute to their distribution and
      elimination.

      The primary purpose of this investigation is to determine whether the herbal supplements
      Echinacea purpurea, ginkgo biloba, and Panax ginseng alter the pharmacokinetic properties of
      the HIV protease inhibitor (PI) lopinavir, administered as the PI combination
      lopinavir/ritonavir (LPV/r). This is an open label pharmacokinetic study that will be
      performed on an outpatient basis. A total of 42 study participants who have met inclusion
      criteria will be sequentially divided into one of 3 groups, such that 14 subjects each will
      receive LPV/r alone and in combination with either E. purpurea, G. biloba, or P. ginseng.

      Subjects will begin taking LPV/r (400mg/100mg twice daily x 29.5 days), returning to the NIH
      on Day 15 of dosing for post-dose plasma collection and determination of lopinavir and
      ritonavir concentrations. On Day 16 participants will begin taking either E. purpurea (500mg,
      three times daily), G. biloba extract (120 mg, twice daily), or P. ginseng (500 mg, twice
      daily) for 28 days. On the 30th day of LPV/r (Day 15 of the herb), subjects will return to
      the NIH where they will take their final LPV/r dose and then have their plasma collected for
      determination of lopinavir concentrations. Data from this investigation will determine
      whether echinacea, ginseng, or ginkgo biloba supplements alter the pharmacokinetics of
      lopinavir.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lopinavir Pharmacokinetics When Administered Alone and in Combination With Three Different Herbal Supplements: Ginkgo Biloba, Panax Ginsing, and Echinacea Purpurea.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba, Echinacea purpurea, or Panax Ginseng).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Effect of G. Biloba on LPV disposition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of Echinacea on LPV disposition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of P. ginseng on LPV disposition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gingko Biloba</intervention_name>
    <description>Ginkgo Biloba 120 mg twice daily for 14 days</description>
    <arm_group_label>Effect of G. Biloba on LPV disposition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Echinacea purpurea</intervention_name>
    <description>Echinacea purpurea 500 mg three times daily for 14 days</description>
    <arm_group_label>Effect of Echinacea on LPV disposition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panax ginseng</intervention_name>
    <description>Panax ginseng 500 mg twice daily</description>
    <arm_group_label>Effect of P. ginseng on LPV disposition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Males and females between the ages of 18 and 50 years.

               2. Healthy by medical history and physical exam.

               3. Laboratory values within established guidelines for participation in clinical
                  studies: AST less than or equal to 2 times the ULN; SCr less than or equal to
                  ULN; hemoglobin equal to or greater than 11 g/dL (for both males and females).

               4. Ability to abstain from ingesting fruit juice during pharmacokinetic sampling
                  periods (a total of 2 study days), and abstain from eating grapefruit or drinking
                  grapefruit juice during the entire study period.

               5. Negative serum or urine pregnancy test for females of child-bearing potential.

               6. Females of child-bearing potential who are able and willing to practice
                  abstinence or use non-hormonal effective methods of birth control during the
                  study, such as condoms or diaphragms.

        EXCLUSION CRITERIA:

          1. Concomitant routine therapy with any prescription, over-the-counter, herbal, or
             holistic medications, including oral contraceptives, for 30 days prior to study
             participation. Intermittent use of any medication within 30 days prior to screening
             will be considered case by case by the principal investigator and the medically
             accountable investigator.

               -  Concomitant therapy (chronic or intermittent) with any prescription,
                  over-the-counter, or herbal drugs (including tinctures, foods, beverages, and
                  gum) will not be allowed during the study duration, including any intermittent
                  use of allergy medication.

               -  Intermittent use of acetaminophen, non-steroidal anti-inflammatory medications
                  (i.e. ibuprofen), and loperamide will be allowed during the study, but should not
                  be taken on the days of pharmacokinetic blood sampling.

               -  A daily multivitamin with minerals will be allowed during the study.

          2. Inability to obtain venous access for blood sample collection.

          3. The presence or history of any of the following: diabetes mellitus (clinical diagnosis
             based on current guidelines, HIV infection, active tuberculosis, cardiac disease (eg.
             Hypertension [SBP greater than 140 mmHG or DBP greater than 90 mmHG], heart failure,
             arrhythmia, etc.), renal disease, hepatitis or hepatic impairment, pancreatitis,
             bleeding disorders, internal bleeding (such as gastrointestinal or intracranial),
             respiratory disease (eg. asthma requiring maintenance pharmacologic therapy, chronic
             obstructive pulmonary disease, etc.), peptic ulcer disease, osteoporosis,
             osteonecrosis, atopy or atopic dermatitis, hormone sensitive cancers or conditions,
             organ transplant, seizure disorders, schizophrenia or other psychiatric illnesses that
             may interfere with the subject's ability to participate in the study, or any other
             condition that may interfere with the interpretation of the study results or not be in
             the best interest of the subject in the opinion of the investigators.

          4. Plans for elective surgery during the investigation or within 1 month following
             completion for subjects in the gingko biloba arm of the study.

          5. Positive serum or urine pregnancy test or breastfeeding female.

          6. The presence of persistent diarrhea or malabsorption that would interfere with the
             subject's ability to absorb drugs.

          7. Drug or alcohol abuse that may impair safety or adherence (more than 3 alcoholic
             drinks per day, on a daily basis).

          8. History of intolerance or allergic reaction to any products containing echinacea,
             ginkgo biloba extract, or ginseng (including pills, tinctures, foods, beverages, and
             gum).

          9. History of intolerance or allergic reaction to lopinavir, ritonavir, midazolam, or
             fexofenadine.

         10. History of atopy including atopic dermatitis, bronchial asthma, multiple food
             allergies, or severe recurring allergic rhinitis.

         11. Fasting total cholesterol greater than 240 mg/dL or fasting triglycerides greater than
             400 mg/dL.

         12. Use of nicotine-containing tobacco products, including cigarettes and chewing tobacco.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott R Penzak, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2005-CC-0082.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998 Nov 9;158(20):2257-64.</citation>
    <PMID>9818806</PMID>
  </reference>
  <reference>
    <citation>Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998 Nov 11;280(18):1569-75.</citation>
    <PMID>9820257</PMID>
  </reference>
  <reference>
    <citation>Risa KJ, Nepon L, Justis JC, Panwalker A, Berman SM, Cinti S, Wagener MM, Singh N. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int J STD AIDS. 2002 Oct;13(10):706-13.</citation>
    <PMID>12396542</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2005</study_first_submitted>
  <study_first_submitted_qc>February 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2005</study_first_posted>
  <results_first_submitted>December 12, 2011</results_first_submitted>
  <results_first_submitted_qc>March 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2012</results_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiretrovirals</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Herbal Supplements</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy human volunteers were recruited to participate in this study throughout the course of the investigation (2005-2010).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Influence of Ginkgo Biloba on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir + ritonavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Ginkgo Biloba administration (120 mg two times daily) to healthy human volunteers.</description>
        </group>
        <group group_id="P2">
          <title>Influence of Echinacea on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir + ritonavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Echinacea(500 mg three times daily).</description>
        </group>
        <group group_id="P3">
          <title>Influence of Panax Ginseng on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Panax ginseng (500 mg twice daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject non-compliant with medications</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influence of Ginkgo Biloba on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir + ritonavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Ginkgo Biloba administration (120 mg two times daily) to healthy human volunteers.</description>
        </group>
        <group group_id="B2">
          <title>Influence of Echinacea on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir + ritonavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Echinacea(500 mg three times daily).</description>
        </group>
        <group group_id="B3">
          <title>Influence of Panax Ginseng on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Panax ginseng (500 mg twice daily).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="9.3"/>
                    <measurement group_id="B2" value="33" spread="8.5"/>
                    <measurement group_id="B3" value="32" spread="6.4"/>
                    <measurement group_id="B4" value="33" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir Pharmacokinetics When Administered Alone and in Combination With Three Different Herbal Supplements: Ginkgo Biloba, Panax Ginsing, and Echinacea Purpurea.</title>
        <description>The outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba, Echinacea purpurea, or Panax Ginseng).</description>
        <time_frame>2 weeks</time_frame>
        <population>Data was analyzed from all subjects who completed a particular sampling period.</population>
        <group_list>
          <group group_id="O1">
            <title>Influence of Ginkgo Biloba on Lopinavir Disposition</title>
            <description>Lopinavir pharmacokinetics (administered as lopinavir-ritonavir X 2 weeks) determined before, and after 14 days of Ginkgo Biloba administration (120 mg two times daily) to healthy human volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Influence of Echinacea on Lopinavir Disposition</title>
            <description>Lopinavir (administered as lopinavir-ritonavir X 2 weeks)pharmacokinetics determined before, and after 14 days of Echinacea purpurea administration (500 mg three times daily) to healthy human volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Influence of Panax Ginseng on Lopinavir Disposition</title>
            <description>Lopinavir (administered as lopinavir-ritonavir X 2 weeks)pharmacokinetics determined before, and after 14-28 days of Panax ginseng (500 mg twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir Pharmacokinetics When Administered Alone and in Combination With Three Different Herbal Supplements: Ginkgo Biloba, Panax Ginsing, and Echinacea Purpurea.</title>
          <description>The outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba, Echinacea purpurea, or Panax Ginseng).</description>
          <population>Data was analyzed from all subjects who completed a particular sampling period.</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.67" upper_limit="1.38"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.83" upper_limit="1.10"/>
                    <measurement group_id="O3" value="1" lower_limit="0.3" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Influence of Ginkgo Biloba on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir + ritonavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Ginkgo Biloba administration (120 mg two times daily) to healthy human volunteers.</description>
        </group>
        <group group_id="E2">
          <title>Influence of Echinacea on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir + ritonavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Echinacea(500 mg three times daily).</description>
        </group>
        <group group_id="E3">
          <title>Influence of Panax Ginseng on Lopinavir/Ritonavir Disposition</title>
          <description>Lopinavir (x 2 weeks), midazolam (single dose), and fexofenadine (single dose) pharmacokinetics determined before, and after 14-28 days of Panax ginseng (500 mg twice daily).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased serum albumin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>decreased hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="26" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E3" events="22" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>taste alterations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>generalized pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated ALT (SGPT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>elevated AST (SGOT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>elevated serum bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased absolute neutrophil count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>acute sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>electrolyte imbalance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypercholesterolemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>decreased concentration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>dysmenorrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Penzak</name_or_title>
      <organization>National Institutes of Health, Clinical Center, Department of Pharmacy</organization>
      <phone>301-496-2997</phone>
      <email>spenzak@cc.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

